economybharat.com

We Can Cover You
Click here
Facebook Youtube Instagram Linkedin
13
13

Diseases

Fujirebio and Eisai Enter into Memorandum of Understanding for Joint Research and Social Implementation of Blood-based Biomarkers in the Field of Neurodegenerative Diseases OG_NewsReleaseCompanyLogo_92984.jpg

Fujirebio and Eisai Enter into Memorandum of Understanding for Joint Research and Social Implementation of Blood-based Biomarkers in the Field of Neurodegenerative Diseases

creativebharatgroup@gmail.com December 23, 2024
TOKYO, Japan:   Fujirebio Holdings, Inc. (President & CEO: Goki Ishikawa; Head Office:...
Read More Read more about Fujirebio and Eisai Enter into Memorandum of Understanding for Joint Research and Social Implementation of Blood-based Biomarkers in the Field of Neurodegenerative Diseases
RenaissThera Closes Seed Funding to Drive AI-Powered Therapies for Cardio-Metabolic Diseases renaissthera_2024_logo.png

RenaissThera Closes Seed Funding to Drive AI-Powered Therapies for Cardio-Metabolic Diseases

creativebharatgroup@gmail.com December 10, 2024
Bengaluru, Karnataka, India RenaissThera Private Limited (“RenaissThera”), a pioneering Bengaluru-based biotechnology company, has successfully...
Read More Read more about RenaissThera Closes Seed Funding to Drive AI-Powered Therapies for Cardio-Metabolic Diseases
PopVax Announces that the U.S. National Institute of Allergy and Infectious Diseases will Conduct and Sponsor the U.S.-based Phase I Clinical Trial of PopVax’s Next-Generation mRNA-LNP COVID-19 Vaccine as part of the U.S. Government’s Project NextGen OG_Companylog_92449.jpg

PopVax Announces that the U.S. National Institute of Allergy and Infectious Diseases will Conduct and Sponsor the U.S.-based Phase I Clinical Trial of PopVax’s Next-Generation mRNA-LNP COVID-19 Vaccine as part of the U.S. Government’s Project NextGen

creativebharatgroup@gmail.com November 14, 2024
MUMBAI, India & HYDERABAD, India:  PopVax, an Indian full-stack biotechnology company developing novel...
Read More Read more about PopVax Announces that the U.S. National Institute of Allergy and Infectious Diseases will Conduct and Sponsor the U.S.-based Phase I Clinical Trial of PopVax’s Next-Generation mRNA-LNP COVID-19 Vaccine as part of the U.S. Government’s Project NextGen